- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04024124
A Ring-type Wearable Device for Atrial Fibrillation Among Ambulatory Patients
16 mars 2020 uppdaterad av: Eue-Keun Choi, Seoul National University Hospital
CART Phase 3 Study: Diagnostic Performance of a Ring-type Wearable Device Using Deep Learning Analysis of Photoplethysmographic Signals for Detecting Atrial Fibrillation Among Ambulatory Patients
This study investigates diagnostic performance of a ring-type wearable device for detecting atrial fibrillation.
This is a prospective cohort registry study began after the date of IRB approval and until 31th Dec. 2023.
The eligible criteria are (1) those who admitted the institution for elective direct-current cardioversion or catheter ablation of persistent atrial fibrillation, (2) those who were successfully converted to sinus rhythm after the intervention, and (3) aged 19 years or more.
The exclusion criteria are (1) those aged less than 19 years, (2) those who are not converted to sinus rhythm after the intervention, and (3) those who are not eligible to measure photoplethysmographic signals.
This study aims to recruit 100 participants in total.
The participants are required to record photoplethysmographic signals by the ring device in addition to routine procedures of direct-current cardioversion or catheter ablation, hence, the study is at minimal risk.
Studieöversikt
Status
Rekrytering
Betingelser
Detaljerad beskrivning
- Study title: Diagnostic Performance of a Ring-type Wearable Device Using Deep Learning Analysis of Photoplethysmographic Signals for Detecting Atrial Fibrillation Among Ambulatory Patients.
- Study type: Investigator initiated study.
- Study design: Prospective observational cohort registry design.
- Sponsor: Sky Labs, Inc., Republic of Korea.
- The aim of the study: To evaluate diagnostic performance of a ring-type wearable device for detecting atrial fibrillation among ambulatory patients.
- Study period: From the date of IRB approval to 31th Dec. 2023.
- The size of study population: 100 participants
- The eligibility criteria:
(1) Those with persistent atrial fibrillation (2) Those who admitted the institution for elective direct-current cardioversion or catheter ablation (3) Those who are successfully converted to sinus rhythm (4) Those aged 19 years or more
9. The exclusion criteria:
- Those with other forms of cardiac arrhythmias
- Those aged less than 19 years
- Those who are not eligible to perform electrical cardioversion or catheter ablation
- Those who are not converted to sinus rhythm after the intervention
10. Procedures of the study
- A participant is under the routine procedures of direct- current cardioversion or catheter ablation.
- On admission, a participant is given with detailed information of the study.
- After the informed consent, the only additional procedure due to the study is recording photoplethysmographic signal by wearing a ring-type device. The participant is instructed how to use the ring device.
- Recorded signals are evaluated without encompassing persornal information.
- The participant is required to wear the ring device and Holter monitoring device, and record his or her photoplethysmographic signals with ambulatory electrocardiography during the day. The ring is designed to automatically record user's photoplethysmographic signals and wirelessly transmit the data to user's smartphone. Detailed timings of wearing on/off the ring device and the Holter device are informed by a designated research crew.
- The participant visits outpatient clinic as scheduled accordingly. At the clinic, the participant returns the ring device, Holter monitoring device, and the recorded data to the designated researcher crew.
- Throughout the study, there is no intervention to the participants. The only additional step due to the participation of the study is that wearing the ring device and Holter monitoring device during their daily lives until the next outpatient clinic.
11. Financial benefits to the participants: None.
Studietyp
Observationell
Inskrivning (Förväntat)
100
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Eue-Keun Choi, MD, PhD
- Telefonnummer: +82-2-2072-0688
- E-post: choiek417@gmail.com
Studera Kontakt Backup
- Namn: Soonil Kwon, MD
- Telefonnummer: +82-10-9498-1664
- E-post: david.soonil.kwon@gmail.com
Studieorter
-
-
-
Seoul, Korea, Republiken av, 03080
- Rekrytering
- Seoul National university Hostpital
-
Kontakt:
- Euekeun Choi, M.D. Ph.D.
- Telefonnummer: 82+02-2072-0688
- E-post: choiek417@gmail.com
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
19 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Testmetod
Icke-sannolikhetsprov
Studera befolkning
The study consecutively recruits participants who admitted for elective direct-current cardioversion or catheter ablation due to persistent atrial fibrillation.
Beskrivning
Inclusion Criteria:
- Those with persistent atrial fibrillation
- Those who admitted for elective direct-current cardioversion or catheter ablation
- Those who are successfully converted to sinus rhythm
- Those who aged 19 years or more
Exclusion Criteria:
- Those who aged less than 19 years
- Those who had other types of cardiac arrhythmias
- Those who are not eligible to perform electrical cardioversion or catheter ablation
- Those who are not converted to sinus rhythm
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Diagnostic performance
Tidsram: 1 month (from the discharge to the next outpatient clinic)
|
Diagnostic performance of a ring-type wearable device for detecting atrial fibrillation (parameters including sensitivity, specificity, positive predictive value, negative predictive value).
|
1 month (from the discharge to the next outpatient clinic)
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Samarbetspartners
Utredare
- Huvudutredare: Eue-Keun Choi, MD, PhD, Devision of Cardiology, Department of Internal Medicine, Seoul National University Hospital
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
10 maj 2019
Primärt slutförande (Förväntat)
1 augusti 2023
Avslutad studie (Förväntat)
1 augusti 2023
Studieregistreringsdatum
Först inskickad
16 juli 2019
Först inskickad som uppfyllde QC-kriterierna
16 juli 2019
Första postat (Faktisk)
18 juli 2019
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
18 mars 2020
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
16 mars 2020
Senast verifierad
1 mars 2020
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CART3
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
OBESLUTSAM
IPD-planbeskrivning
Currently, according to the decision with IRB of the institution, the IPD is not planned to be shared with other researchers for the purpose of protecting potential privacy issues of the participants.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .